No profile data available.
ALK-Abelló A/S (ALK-B.CO) is a healthcare company in the allergy treatment pharmaceuticals industry, based in Horsholm, Denmark, with about 2,773 full-time employees.
It reported revenue of 6.31 billion DKK for fiscal year 2025, up 14.0% from fiscal year 2024, and net income of 1.20 billion DKK. In Q1 2026 (the quarter ended March 31, 2026) revenue was 1.77 billion DKK, up 16.4% from a year before. Its market capitalization was 50.39 billion DKK as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally.
ALK-Abelló A/S reported 6.31 billion DKK in revenue for fiscal year 2025, up 14.0% from 5.54 billion DKK in fiscal year 2024. In Q1 2026 revenue was 1.77 billion DKK.
50.39 billion DKK as of October 9, 2026.